Weight loss clinics in columbia sc
Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3. Abstract Background Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. The sponsor, Novo Nordisk, planned and performed the statistical analyses, provided editorial and writing assistance, and provided the trial drugs. All the authors were involved in the design or conduct of the study and the preparation of the manuscript, including the decision to submit it for publication, and all attest to the accuracy and completeness of data and the data analyses. Methods Study Overview We conducted the study from June 1, 2011, through March 18, 2013, at 191 sites in 27 countries in Europe, North America, South America, Asia, Africa, and Australia. Details of the eligibility and exclusion criteria are provided in the Supplementary Appendix.
Media in This Article QUICK TAKE VIDEO SUMMARY The SCALE Trial Figure 1 Liraglutide and Body Weight. Figure 2 Liraglutide and Glucose Levels during Oral Glucose-Tolerance Test and Glycemic Status. Key exclusion criteria were type 1 or 2 diabetes, the use of medications that cause clinically significant weight gain or loss, previous bariatric surgery, a history of pancreatitis, a history of major depressive or other severe psychiatric disorders, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. Study Design and Treatments Randomization was performed with the use of a telephone or Web-based system provided by the sponsor. 0 mg, injected subcutaneously. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight.
